Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Market Chatter: JD.com Facing Criticism Over Concessions to Clear Ceconomy Acquisition in EU

Market Chatter: JD.com Facing Criticism Over Concessions to Clear Ceconomy Acquisition in EU

MT newswireMT newswire2026/09/11 08:49
04:49 AM EDT, 09/11/2026 (MT Newswires) -- JD.com (JD) rivals are criticizing the company's proposed concessions to clear its acquisition of electronics retailer Ceconomy with the European Commission, Reuters reported Thursday, citing unnamed sources familiar with the matter. One of the sources told Reuters that the concessions include Ceconomy maintaining access to JD.com's European logistics and technological capabilities at market rates. The European Commission has already responded to JD.com's concessions earlier this week and is set to decide on the acquisition by Oct. 23, according to the report. JD.com and the European Commission did not immediately respond to MT Newswires' requests for comments. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12